title: [Main principles of correction of blood circulation disorders in the early postresuscitation period].
abstract: Experiments with 386 dogs and 365 cats revealed that, irrespective of the cause of clinical death, the animals develop in the postresuscitation period phasic changes of the systemic and local circulation manifesting by a short-term increase of volumetric perfusion, followed by its decrease and gradual normalization. The most favorable course of repair processes was observed after short (3 to 5 min) hyperperfusion with the supradiaphragmatic fraction increased by 25-30%. Development of the hypoperfusion syndrome at the first stage after resuscitation (3 to 60 min) is determined by the depression of cardiac contractility. Cardiac output at this stage is maintained by moderate cardiotonic therapy (dopamine). Subsequent reduction of volumetric perfusion during 1 to 9 h of the postresuscitation period is caused mainly by the hydro-ionic disorders leading to development of hypovolemia and the hyperviscosity syndrome associated with it. Systemic and local circulation is normalized at this stage by volemic (polygluquin), dehydration (mannitol), antistressor (dalargin), and membrane-stabilizing (lidocaine) therapy. After 24 h, during the phase of circulation normalization, it is advisable to administer membrane-stabilizing and detoxifying, and, if necessary (in case of a myocardial infarction), antiarrhythmic therapy.
authors.forename: A Ia
authors.initials: AIa
authors.lastname: Evtushenko
authors.forename: G V
authors.initials: GV
authors.lastname: Lisachenko
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002415:Cats; D004285:Dogs; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D009200:Myocardial Contraction; D012151:Resuscitation / Q000009:adverse effects*; D013565:Sympatholytics / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D013565:Sympatholytics; D008353:Mannitol; D016308:Enkephalin, Leucine-2-Alanine; D008012:Lidocaine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
vernacular_title: Osnovnye printsipy korrektsii narusheniĭ krovoobrashcheniia v rannem postreanimatsionnom periode.